Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.50 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13021616 | 0.86 | ROCK2 (0.46) | ROCK2ROCK1 | |
| SCHEMBL23927664 | 0.83 | ROCK2 (0.68) | ROCK2ROCK1MYLK4 | |
| SCHEMBL9883142 | 0.82 | ROCK2 (0.66) | ROCK2ROCK1MYLK4 | |
| Hydrochloric Acid SCHEMBL112565 | 0.81 | ROCK2 (0.65) | ROCK2ROCK1MYLK4 | |
| SCHEMBL113963 | 0.80 | ROCK2 (0.53) | ROCK2ROCK1MYLK4 | |
| SCHEMBL113952 | 0.78 | ROCK2 (0.53) | ROCK2ROCK1MYLK4 | |
| SCHEMBL2816916 | 0.76 | ROCK2 (0.54) | ROCK2ROCK1 | |
| SCHEMBL2778216 | 0.75 | ROCK2 (0.47) | ROCK2ROCK1MYLK4 | |
| SCHEMBL23398166 | 0.75 | ROCK2 (0.47) | ROCK2ROCK1MYLK4 | |
| SCHEMBL20078718 | 0.75 | ROCK2 (0.52) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | ROCK2 2/4885ROCK1 6/4885MYLK4 196/4885 |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.